C2N Diagnostics, a leader in advanced brain health diagnostics, announced the presentation of two research studies at the AD/PD 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders that bolster the role of the Precivity-related blood biomarkers (BBM) to help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease (AD). These findings underscore the ability of the Precivity-related BBM to help clinicians with the diagnosis of AD in cognitively impaired patients as well as risk prediction in unimpaired individuals.
PrecivityAD2 blood test shows robust accuracy in real-world study
Dr. Sebastian Palmqvist and Dr. Oskar Hansson, neurologists with Skåne University Hospital and Lund University in Sweden, used the PrecivityAD2 blood test that relies on precise mass spectrometry-based measurements of two key plasma proteins implicated in AD. The blood test reports out plasma p-tau217 Ratio and plasma Aβ42/40 Ratio measures as well as the Amyloid Probability Score 2 (APS2) derived from a pre-established regression model based on those ratio measures. The APS2 results determine whether a patient is positive or negative for brain amyloid plaques based on a binary cutoff value.
The study included 307 patients with symptoms of cognitive impairment evaluated within primary care sites in Sweden. All patients received the PrecivityAD2 blood test as well as cerebrospinal fluid (CSF) analysis or an amyloid positron emission tomography (PET) scan. The Precivity-related BBM showed robust discrimination between amyloid positive and amyloid negative patients using CSF or PET biomarkers as the reference tests. In particular, the AUC of 0.91 for p-tau217 Ratio and AUC of 0.94 for the APS2 result were noted.
Dr. Palmqvist says, “The primary care physicians’ diagnosis certainty with standard of care only was low, which highlights that they are completely aware that currently available diagnostic tools in primary care are not adequate. The results we’ve seen so far indicate that this can radically change with a blood test for AD. The blood biomarkers showed robust clinical validity and accuracy among patients with comorbidities known to interfere with the performance of plasma. The PrecivityAD2 data represent the highest correlation data I’ve seen for a blood test against corresponding CSF biomarkers.”
SOURCE: Businesswire